GlassScriptPhysician profile
Darryl S Hodson
NPI 1871583351
$4,188.45
in general payments reported to CMS, 2019-2025
24 companies · $717 in 2025
The $717 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $275 · 2021: $405 · 2022: $771 · 2023: $895 · 2024: $776 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,372 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.59 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,136.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $853.51 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $414.70 | 2019-2025 | |
| Amgen INC. | $385.75 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $245.20 | 2022-2025 | |
| Incyte Corporation | $155.99 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $133.23 | 2020-2025 | |
| Janssen Biotech, INC. | $103.14 | 2019-2023 | Simponi Aria, Simponi, Remicade |
| Pfizer INC. | $100.05 | 2020-2025 | |
| Dermavant Sciences, INC. | $88.70 | 2023-2024 | Vtama |
| Genentech USA, INC. | $87.70 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $74.71 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.78 | 2019-2024 | Siliq, Duobrii, Targretin |
| Ucb, INC. | $66.03 | 2025 | Bimzelx |
| Lilly USA, LLC | $55.54 | 2019-2023 | Taltz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $53.58 | 2021-2024 | |
| Organon LLC | $35.00 | 2025 | Vtama |
| Leo Pharma INC. | $29.68 | 2020 | |
| Biofrontera INC. | $18.86 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Stemline Therapeutics INC. | $17.85 | 2021 | |
| Merck Sharp & Dohme LLC | $17.25 | 2022 | |
| Kerecis Limited | $15.59 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.34 | 2024 | Spevigo |
| Next Science LLC | $10.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Hodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.